BrainsWay Begins Trials of Rotation Field Deep TMS 360 Technology

BrainsWay, a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, recently announced it will be clinically evaluating patented “Rotational Field” technology in two new feasibility trials.
 
Both studies will utilize BrainWay’s Rotational Field TMS or Deep TMS 360° which employs a method of stimulation that enables activation of a greater number of neurons in the brain. 
 
With the new system now being evaluated, two orthogonal TMS coils are placed perpendicular to each other and are operated with a time lag to induce a circularly rotating electronic field. Within less than a millisecond this creates uniform stimulation of neurons oriented along a wide variety of directions in the targeted brain region. 
 
One study is to test the safety and efficacy of this technology in stroke rehabilitation, and the other study will use an accelerated protocol to assess obsessive-compulsive disorder (OCD). 
 
The company’s existing Deep Transcranial Magnetic Stimulation (Deep TMS) system is FDA-cleared to treat OCD using standard daily protocol through its H7 Coil. This new study will test the ability to further improve outcomes using Rotational Field stimulation while reducing the length of the standard treatment.
 
CEO Hadar Levy told the press, “We are proud to continue to be at the forefront of innovation in the field of noninvasive brain stimulation. We believe that our Rotational Field technology holds significant potential to change the current TMS paradigm. We look forward to testing its capabilities in these newly launched post-stroke rehabilitation and OCD feasibility studies.”
 
The company’s Rotational Field technology has not yet been cleared for safety and/or efficacy by the FDA and is not commercially available.
 
Founded in 2033, BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications that are backed by clinical studies demonstrating its efficacy. Current indication includes major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is located in Burlington, MA and Jerusalem, Israel.